CASI Pharmaceuticals Inc.

CASIF Healthcare Biotechnology

CASI Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $20.7 million, down 27.4% from fiscal 2024. In the quarter to December 2025, revenue fell 45.9%, EPS grew 54.4%, free cash flow fell 23,251.7% and total debt rose 6.97%, each against the same quarter a year earlier.

0.10 0.00 0.00%
Market cap
$12.4M
P/E
0.0×
Fwd P/E
−0.1×
Dividend yield
—
F-score
4/9
Altman Z
−47.08
Beneish M
−8.73
Dividend safety
n/a
Older periods Jun '25 Sep '25 Dec '25 Jun '26
Piotroski F-Score

+8 more TTM periods

— — 3 —
ROE
830.72% 669.76% 271.28% 0.00%
ROA
(113.71%) (112.12%) (121.17%) 0.00%
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
385.20% 242.48% 164.33% 0.00%
Average Days of Receivables
62.02 35.47 72.11 0.00
Free Cash Flow per Share
0.00 0.00 (3.80) —
Free Cash Flow
— — (70.46) —
Other line items

Show all line items

Columns are period end dates